Financing channel feed – Endpoints News

Financing channel feed

In the hunt for a $100M IPO, Biohaven polishes up discards from Bristol-Myers, AstraZeneca

9 years ago

Armed with deals, dollars and the promise of upcoming data, Zymeworks files $75M IPO

9 years ago

Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy

9 years ago

Money, brains and ambition: Third Rock startup Tango launches with $55M and a stellar crew of scientific advisers

9 years ago

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

9 years ago

Novartis-backed Ionis subsidiary Akcea maps a $100M IPO as it steers a lead drug to regulators

9 years ago

That $95M Merck gamble to acquire cCAM? It didn’t pay off.

9 years ago

BioClin scores a $30M raise from marquee investors to fuel mid-stage work on a new cancer drug

9 years ago

SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines

9 years ago

New biotech venture fund debuts with $300M for a mix of US and European players

9 years ago

Gates vets raise a $200M life sci fund for avant-garde genomic biotechs and digital health players

9 years ago

On again, ex-Google superstar Bill Maris is said to bankroll a $100M biotech fund

9 years ago

Pushing ahead with cancer drug research, Peloton brings its latest round to $75M

9 years ago

Tocagen shoots for $86 million IPO, spotlighting a high-risk shot at a quick OK for brain cancer therapy

9 years ago

Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics

9 years ago

Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition

9 years ago

OrbiMed doubling down on Asia biotech bets with $450M fund

9 years ago

Alta Partners sketches plans to raise $200M for its next life sciences venture fund

9 years ago

Going big: Biotech vets blast off with Arrakis on a new journey of RNA exploration

9 years ago

Looking to an IPO? Rhythm raises $41M to pay for pivotal trials

9 years ago

Serono spinout grabs a $31M round for a pair of proof-of-concept Parkinson’s trials

9 years ago

Biotech dealmaker Ramaswamy raises another $55M for Axovant

9 years ago

Versant backs a rebooted Tarveda with $30M round for pipeline development

9 years ago

Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford

9 years ago

First page Previous page 140 141 142143144 145 Next page Last page